Toll-like receptors, transduction-effector pathways, and disease diversity: Evidence of an immunobiological paradigm explaining all human illness?

International Reviews of Immunology

Volumn 27, Issue 4, 2008, Pages 255-281

  Atkinson, Timothy J ^a  

^a NONE   (United Kingdom)

Author keywords

Disease; Diversity; Immunology; Pathogenesis; Signal transduction; Toll like receptors

Indexed keywords

TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9;

ACNE; ACUTE PANCREATITIS; ADAPTIVE IMMUNITY; ALLERGY; ALZHEIMER DISEASE; ASTHMA; ATHEROSCLEROSIS; AUTOIMMUNITY; BASAL CELL CARCINOMA; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CELIAC DISEASE; CEREBROVASCULAR DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC PAIN; COLITIS; COLORECTAL CARCINOMA; CONJUNCTIVITIS; CORONARY ARTERY DISEASE; CROHN DISEASE; CYSTIC FIBROSIS; DEGENERATIVE DISEASE; ENDOTHELIAL DYSFUNCTION; ENTERITIS; EYE INFLAMMATION; FOOD ALLERGY; GASTROINTESTINAL DISEASE; GENE EXPRESSION; GLIOBLASTOMA; HEART INFARCTION; HEMATOLOGIC DISEASE; HEMORRHAGIC SHOCK; HUMAN; IMMUNOMODULATION; INFLAMMATION; INFLAMMATORY DISEASE; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER DISEASE; LUNG DISEASE; LUNG EMPHYSEMA; LYMPHOMA; MELANOMA; MICROORGANISM; MULTIPLE SCLEROSIS; MUSCULOSKELETAL DISEASE; NECROTIZING ENTEROCOLITIS; NEOPLASM; NEPHRITIS; NEUROLOGIC DISEASE; OBSTETRICS; OTITIS MEDIA; PATHOGENESIS; PERIODONTITIS; PREMATURITY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN STRUCTURE; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATIC FEVER; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SEPSIS; SIGNAL TRANSDUCTION; SKIN DISEASE; SPONDYLOARTHROPATHY; STEVENS JOHNSON SYNDROME; STOMACH CANCER; STROKE; SURGICAL INJURY; SYSTEMIC LUPUS ERYTHEMATOSUS; TISSUE INJURY; TISSUE REGENERATION; ULCERATIVE COLITIS; UTERINE CERVIX CANCER; WOUND HEALING;

CARDIOVASCULAR DISEASES; COMMUNICABLE DISEASES; GASTROINTESTINAL DISEASES; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNITY; MODELS, IMMUNOLOGICAL; NEOPLASMS; NERVOUS SYSTEM DISEASES; SIGNAL TRANSDUCTION; SKIN DISEASES; STRUCTURE-ACTIVITY RELATIONSHIP; TOLL-LIKE RECEPTORS;

EID: 46049120813     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.1080/08830180801959072     Document Type: Review

References (197)

1. E.B. Kopp and R. Medzhitov, The toll-receptor family and control of innate immunity. Curr Opin Immunol., 11: 13-18, 1999.
2. E.B. Kopp and R. Medzhitov, Recognition of microbial infection by Toll-like receptors. Curr Opin Immunol., 15: 396-401, 2003.
3. D.M. Underhill and A. Ozinsky, Toll-like receptors: key mediators of microbe detection. Curr Opin Immunol., 14: 103-110, 2002.
4. J.M. Schuster and P.S. Nelson, Toll receptors: an expanding role in our understanding of human disease. J Leukoc Biol., 67: 767-773, 2000.
5. R. Medzhitov and C.A. Janeway, Jr., Innate immunity: the virtues of a nonclonal system of recognition. Cell, 91: 295-298, 1997.
6. B. Beutler, K. Hoebe, X. Du, and R.J. Ulevitch, How we detect microbes and respond to them: the Toll-like receptors and their transducers. J Leukoc Biol, 74: 479-485, 2003.
7. S. Janssens and R. Beyaert, Role of Toll-like receptors in pathogen recognition. Clin Microbiol Rev., 16: 637-646, 2003.
8. S. Mukhopadhyay, J. Herre, G.D. Brown, and S. Gordon, The potential for Toll-like receptors to collaborate with other innate immune receptors. Immunology, 112: 521-530, 2004.
9. A.G. Bowie, Translational mini-review series on Toll-like receptors: recent advances in understanding the role of Toll-like receptors in anti-viral immunity. Clin Exp Immunol, 147: 217-26, 2007.
10. G. Liu and Y. Zhao, Toll-like receptors and immune regulation: their direct and indirect modulation on regulatory CD4+ CD25+ T cells. Immunology, 122(2): 149-156, 2007.
11. B. Kobe and J. Deisenhofer, The leucine rich repeat: a versatile binding motif. Trends Biochem Sci., 19: 415-421, 1994.
12. S.G. Buchanan and N.J. Gay, Structural and functional diversity in the leucine-rich repeat family of proteins. Prog Biophys Mol Biol., 65: 1-44, 1996.
13. L.A. O'Neill, Towards an understanding of the signal transduction for interleukin 1. Biochem Biophys Acta., 1266: 31-44, 1995.
14. D.T. Fearon and R.M. Locksley, The instructive role of innate immunity in the acquired immune response. Science, 272: 50-53, 1996.
15. R. Medzhitov, P. Preston-Hurlburt, and C.A. Janeway Jr., A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature, 388: 394-397, 1997.
16. R. De Waal Malefyt, J. Haanen, H. Spits et al., Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via down-regulation of class II major histocompatibility complex expression. J Exp Med, 174: 915-924, 1991.
17. H. Yssel, R. DeWaal Maleftt, M.G. Roncarolo, J.S. Abrams, R. Lahesmaa, H. Spits, and J.E. de Vries, IL-10 is produced by subsets of human CD4+ T cell clones and peripheral blood T cells. J Immunol., 149: 2378-2384, 1992.
18. Z.H. Nemeth, G. Hasko, and E.S. Vizi, Pyrrolidine dithiocarbamate augments IL-10, inhibits TNF-alpha, MIP-1, IL-12 and nitric oxide production and protects from the lethal effects of endotoxin. Shock, 10: 49-53, 1998.
19. H.D. Brightbill, S.E. Plevy, R.L. Modlin, and S.T. Smale, A promonent role for Sp1 during LPS-mediated induction of the IL-10 promoter in macrophages. J Immunol., 164: 1940-1951, 2000,
20. A.O. Aliprantis, R.B. Yang, M.R. Mark, et al., Cell activation and apoptosis by bacterial lipoproteins through Toll-liked receptor-2. Science, 285: 736-739, 1999.
21. L.A. O'Neill and C. Greene, Signal transduction pathways activated by the IL-1 receptor family: ancient signaling machinery in mammals, insects, and plants. J Leukoc Biol., 63: 650-657, 1998.
22. P.E. Auron: The interleukin 1 receptor: ligand interactions and signal transduction. Cytokine Growth Factor Rev., 9: 221-237, 1998.
23. R. Medzhitov, P. Preston-Hurlburt, E. Kopp, A. Stadlen, C. Chen, S. Ghosh, and C.A. Janeway, Jr: MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell, 2: 253-258, 1998.
24. M. Muzio, J. Ni, P. Feng, and V.M. Dixit, IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-2 signaling. Science, 278: 1612-1615, 1997.
25. Z. Cao, W.J. Henzel, and X Gao, IRAK: a kinase associated with the interleukin-1 receptor. Science., 271: 1128-1131, 1996.
26. Z. Cao, J. Xiong, M. Takeuchi, T. Kurama, and D.V. Goeddel, TRAF6 is a signal transducer for interleukin-1. Nature, 383: 443-446, 1996.
27. J. Lee, L. Mira-Aribe, and R.J. Ulevitch, TAK1 regulates multiple kinase cascades activated by bacterial lipopolysaccharide. J Leukoc Biol., 68: 909-915, 2000.
28. L.A. O' Neill, K.A. Fitzgerald, and A.G. Bowie, The Toll-IL-1 receptor adaptor family grows to five members. Trends Immunol., 24: 286-290, 2003.
29. T. Kobayashi, M.C. Walsh, and Y. Choi, The role of TRAF6 in signal transduction and the immune response. Microbes Infect., 6: 1333-1338, 2004.
30. J.D. Woronicz, X. Gao, Z. Cao, M. Rothe, and D.V. Goeddel, IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK. Science, 278: 866-869, 1997.
31. N.L. Malinin, M.P. Boldin, A.V. Kovalenko, and D. Wallach, MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1. Nature, 385: 540-544, 1997.
32. P.A. Baeuerle, Proinflammatory signaling: last pieces in the NF-kappaB puzzle? Curr Biol., 8: R19-22, 1998.
33. D.M. Underhill, Toll-like receptors: networking for success. Eur J Immunol., 33: 1767-1775, 2003.
34. R. Medzhitov and C.A. Janeway Jr., Innate immunity: impact on the adaptive immune response. Curr Opin Immunol., 9: 4-9, 1997.
35. K. Ohashi, V. Burkhart, S. Flohe, and H. Kolb, Heat shock protein 60 is a putative endogenous ligand of the Toll-like receptor-4 complex. J Immunol., 164: 558-561, 2000.
36. T. Kawai, O. Adachi, T. Ogawa, and K. Takeda, S. Akira, Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity., 11: 115-122, 1999.
37. V. Toshchakov, B.W. Jones, P.Y. Perera, K. Thomas, M.J. Cody, S. Zhang, B.R. Williams, J. Major, T.A. Hamilton, M.J. Fenton, and S.N. Vogel, TLR4, but not TLR2, mediates IFN-beta-induced STAT1 alpha/beta-dependent gene expression in macrophages. Nat Immunol., 3: 392-398, 2002.
38. H. Wesche, W.J. Henzel, W. Shillinglaw, and S. Li, Z. Cao, MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity., 7: 837-847, 1997.
39. S.E. Plevy, J.H. Gemberling, S. Hsu, A.J. Dorner, and S.T. Smale, Multiple control elements mediate activation of the murine and human interleukin 12 p40 promoters: evidence of functional synergy between C/EBP and Rel proteins. Mol Cell Biol., 17: 4572-4588, 1996.
40. M. Muzio, G. Natoli, S. Saccani, M. Leverero, and A. Mantovani, The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumour necrosis factor receptor-associated factor 6 (TRAF6). J Exp Med., 187: 2097-2101, 1998.
41. H.D. Brightbill and R.L. Modlin, Toll-like receptors: molecular mechanisms of the mammalian immune response. Immunology., 101: 1-10, 2000.
42. T. Kaisho and S. Akira, Dendritic-cell function in Toll-like receptor and MyD88-knockout mice. Trends Immunol., 22: 78-83, 2001.
43. T. de Smedt, B. Pajak, E. Muraille, L. Lespagnard, E. Heinen, P. De Baetselier, J. Urbain, O. Leo, and M. Moser, Regulation of dendritic cell numbers andmaturation by lipopolysaccharide in vivo. J Exp Med., 184: 1413-1424, 1996.
44. J. Banchereau and R.M. Steinman, Dendritic cells and the control of immunity. Nature, 392: 245-252, 1998.
45. A. Mazzoni and D.M. Segal, Controlling the Toll road to dendritic cell polarization. J Leukoc Biol., 75: 721-730, 2004.
46. N. Kadowaki, S. Ho, S. Antonenko, R. de Waal Malefyt, R.A. Kastelein, F. Bazan, and Y.J. Liu, Subsets of dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. J Exp Med., 194: 863-869, 2001.
47. I.L. Qi, T.L. Denning, and L. Soong, Differential induction of interleukin-10 and interleukin-12 in dendritic cells by microbial Toll-like receptor activators and skewing of T-cell cytokine profiles. Infect Immun., 71: 3337-3342, 2003.
48. F. Re and J.L. Strominger, Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J Biol Chem., 276: 37692-37699, 2001.
49. H.K. onda, S. Sakaguchi, C. Nakajima et al., Selective contribution of IFN-alpha/ beta signaling to the maturation of dendritic cells induced by double-stranded RNA or viral infection. Proc Natl Acad Sci. USA, 100: 10872-10877, 2003.
50. A. Iwasaki and R. Medzhitov, Toll-like receptor control of the adaptive immune response. Nat Immunol., 5: 987-995, 2004.
51. O. Froy, Regulation of mammalian defensin expression by Toll-like receptor-dependent and independent signaling pathways. Cell Microbiol., 7: 1387-97, 2005.
52. C. Marsik, F. Mayr, F. Cardona, L. Derhashnig, O.F. Wagner, and B. Jilma, Endotoxaemia modulates Toll-like receptors on leukocytes in humans. Br J Haematol., 121: 653-656, 2003.
53. S.R. Krutzik, M.T. Ochoa, P.A. Sieling, Y.W. Ng, A. Legaspi, P.T. Liu, S.T. Cole, P.J. Godowski, Y. Maeda, E.N. Sarno, M.V. Norgard, P.J. Brennan, S. Akira, T.H. Rea, and R.L. Modlin, Activation and regulation of Toll-like receptors 2 and 1 in human leprosy. Nat Med., 9: 525-532, 2003.
54. L. Alexopoulou, V. Thomas, M. Schnare, Y. Lobet, J. Anguita, R.T. Schoen, R. Medzhitov, E. Fikrig, and R.A. Flavell, Hyporesponsiveness to vaccination with Borrelia burgdorferi AspA in humans and in TLR1-and TLR2-deficient mice. Nat Med., 8: 878-887, 2002.
55. D.M. Agnese, J.E. Galvano, S.J. Hahm, S.M. Coyle, S.A. Corbett, S.E. Calvano, and S.F. Lowry, Human Toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of Gram-negative infections. J Infect Dis., 186: 1522-1525, 2002.
56. E. Lorenz, J.P. Mira, K.L. Frees, and D.A. Schwartz, Relevance of mutations in the TLR4 receptor in patients with Gram-negative septic shock. Arch Intern Med., 162: 1028-1032, 2002.
57. R.C. Read, J. Pullin, S. Gregory, R. Borrow, E.B. Kaczmarski, F.S. di Giovine, S.K. Dower, C. Cannings, and A.G. Wilson, A functional polymorphism of Toll-like receptor 4 is not associated with likelihood or severity of meningococcal disease. J Infect Dis., 184: 640-642, 2001.
58. C. Erridge, J. Stewart, and I.R. Poxton, Monocytes heterozygous for the Asp299Gly and Thr399lle mutations in the Toll-like receptor 4 gene show no deficit in lipopolysaccharide signaling. J Exp Med., 197: 1787-1791, 2003.
59. S. Von Aulock, N.W. Schroder, K. Gueininzius, S. Traub, S. Hoffmann, K. Graf, S. Dimmeler, T. Hartung, R.R. Schumann, and C. Hermann, Heterozygous Toll-like receptor 4 polymorphism does not influence lipopolysaccharide-induced cytokine release in human whole blood. J Infect Dis., 188: 938-943, 2003.
60. A. Sing, D. Rost, N. Tvardovskaia, A. Roggenkamp, A. Wiedemann, C.J. Kirschning, M. Aepfelbacher, and J. Heesemann, Yersinia V.-antigen exploits Toll-like receptor 2 and CD14 for interleukin-10-mediated immunosuppression. J Exp Med., 196: 1017-1024.
61. + regulatory T cells. Eur Cytokine Netw., 14(Suppl), 116 [Abstract].
62. S.J. Jenkins, J.P. Hewitson, G.R. Jenkins, and A.P. Mountford, Modulation of the host's immune response by schistosome larvae. Parasite Immunol., 27: 385-393, 2005.
63. T. Lang and A. Mansell, The negative regulation of Toll-like receptor and associated pathways. Immunol Cell Biol. Aug-Sep., 85: 425-434, 2007.
64. R.L. Modlin, Activation of Toll-like receptors by microbial lipoproteins: role in host defense. J Allergy Clin Immunol., 108(4 Suppl): S104-S106, 2001.
65. R.M. Vabulas, H. Wagner, and H. Schild, Heat shock proteins as ligands of Toll-like receptors. Curr Top Microbiol Immunol., 270: 169-84, 2002.
66. A.F. McGettrick and A. O'L, Neill, Toll-like receptors, key activators of leucocytes and regulator of haematopoiesis. Br J Haematol., 139: 185-193, 2007.
67. B. Salaun, P. Romero, and S. Lebecque, Toll-like receptors' two-edged sword: when immunity meets apoptosis. Eur J Immunol., 37: 3311-3118, 2007.
68. C. Pasare and R. Medzhitov, Toll-like receptors: balancing host resistance with immune tolerance. Curr Opin Immunol., 15: 677-682, 2003.
69. A. Marshak-Rothstein, Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol., 6: 823-835, 2006.
70. R. Seibl, D. Kyburz, R.P. Lauener and S. Gay, Pattern recognition receptors and their involvement in the pathogenesis of arthritis. Curr Opin Rheumatol., 16: 411-418, 2004.
71. E. Toubi and Y. Shoenfeld, Toll-like receptors and their role in the development of autoimmune diseases. Autoimmunity., 37: 183-188, 2004.
72. T.R. Radstake, A.W. van Lieshout, P.L. van Riel, W.B. van den Berg, and G.J. Adema, Dendritic cells, Fc{gamma} receptors, and Toll-like receptors: potential allies in the battle against rheumatoid arthritis. Ann Rheum Dis., 64: 1532-1538, 2005.
73. S.M. Kerfoot, E.M. Long, M.J. Hickey, G. Andonegui, B.M. Lapointe, R.C. Zanardo, C. Bonder, W.G. James, S.M. Robbins, and P. Kubes, TLR4 contributes to disease-inducing mechanisms resulting in central nervous system autoimmune disease. J Immunol., 173: 7070-7077, 2004.
74. I.R. Rifkin, E.A. Leadbetter, L. Busconi, G. Viglianti, A. Marshak-Rothstein, Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev., 204: 27-42, 2005.
75. R.N. Bhattacharjee and S. Akira, Modifying Toll-like receptor 9 signaling for therapeutic use. Mini Rev Med Chem., 6: 287-291, 2006.
76. C. Popa, A.W. van Lieshout, M.F. Roelofs, A. Geurts.-Moespot P.L. van Riel, T. Calandra, F.C. Sweep, and T.R. Radstake, MIF production by dendritic cells is differentially regulated by Toll-like receptors and increased during rheumatoid arthritis. Cytokine., 36: 51-56, 2006.
77. L. Candia, J. Marquez, C. Hernandez, A.H. Zea, and L.R. Espinoza, Toll-like receptor-2 expression is upregulated in antigen-presenting cells from patients with psoriatic arthritis: a pathogenic role for innate immunity? J Rheumatol., 34: 374-379, 2007.
78. L. De Rycke, B. Vandooren, E. Kruithof, F. De Keyser, E.M. Veys, and D. Baeten, Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy. Arthritis Rheum., 52: 2146-2158, 2005.
79. Z.X. Yang, Y. Liang, Y. Zhu, C. Li, L.Z. Zhang, X.M. Zeng, and R.Q. Zhong, Increased expression of Toll-like receptor 4 in peripheral blood leucocytes and serum levels of some cytokines in patients with ankylosing spondylitis. Clin Exp Immunol., 149: 48-55, 2007.
80. T.R. Hawn, H. Wu, J.M. Grossman, B.H. Hahn, B.P. Tsao, and A. Aderem, A stop codon polymorphism of Toll-like receptor 5 is associated with resistance to systemic lupus erythematosus. Proc Natl Acad Sci U S A., 26: 102(30): 10593-10597, 2005.
81. E.D. Papadimitraki, C. Choulaki, E. Koutala, G. Bertsias, C. Tsatsanis, I. Gergianaki, A. Raptopoulou, H.D. Kritikos, C. Mamalaki, P. Sidiropoulos, and D.T. Boumpas, Expansion of Toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis Rheum. 54: 3601-3611, 2006.
82. S.R. Christensen, J. Shupe, K. Nickerson, M. Kashgarian, R.A. Flavell, and M.J. Shlomchik, Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in amurinemodel of lupus. Immunity., 25: 417-428.
83. Comment in: Immunity., 25: 397-379, 2006.
84. F.J. Barrat, T. Meeker, J.H. Chan, C. Guiducci, and R.L. Coffman, Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol., 37: 3582-3596, 2007.
85. S. Nakano, S. Morimoto, J. Suzuki, K. Nozawa, H. Amano, Y. Tokano, and Y. Takasaki, Role of pathogenic auto-antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus. Rheumatology (Oxford), 47(2): 145-149, 2008.
86. Y. Park, S. Park, E. Yoo, D. Kim, and H. Shin, Association of the polymorphism for Toll-like receptor 2 with type 1 diabetes susceptibility. Ann N Y Acad Sci., 1037: 170-174, 2004.
87. M.J. Kolek, J.F. Carlquist, J.B. Muhlestein, B.M. Whiting, B.D. Horne, T.L. Bair, and J.L. Anderson, Toll-like receptor 4 gene Asp299Gly polymorphism is associated with reductions in vascular inflammation, angiographic coronary artery disease, and clinical diabetes. Am Heart J., 148: 1034-1040, 2004.
88. F.J. Pirie, R. Pegoraro, A.A. Motala, S. Rauff, L. Rom, T. Govender, and T.M. Esterhuizen, Toll-like receptor 3 gene polymorphisms in South African Blacks with type 1 diabetes. Tissue Antigens., 66: 125-130, 2005.
89. D. Zipris, E. Lien, J.X. Xie, D.L. Greiner, J.P. Mordes, and A.A. Rossini, TLR activation synergizes with Kilham rat virus infection to induce diabetes in BBDR rats. J Immunol., 174: 131-142, 2005.
90. D. Vallois, C.H. Grimm, P. Avner, C. Boitard, and U.C. Rogner, The type 1 diabetes locus Idd6 controls TLR1 expression. J Immunol., 179: 3896-3903, 2007.
91. H.S. Kim, M.S. Han, K.W. Chung, S. Kim, E. Kim, M.J. Kim, E. Jang, H.A. Lee, J. Youn, S. Akira, and M.S. Lee, Toll-like receptor 2 senses beta-cell death and contributes to the initiation of autoimmune diabetes. Immunity., 27: 321-333, 2007.
92. J.A. Lawton, and P. Ghosh, Novel therapeutic strategies based on Toll-like receptor signaling. Curr Opin Chem Biol., 7: 446-451, 2003.
93. S.C. Gangloff, and M. Guenounou, Toll-like receptors and immune response in allergic disease. Clin Rev Allergy Immunol., 26, 115-125, 2004.
94. G. Velasco, M. Campo, O.J. Manrique, A. Bellou, H. He, R.S. Arestides, B. Schaub, D.L. Perkins, and P.W. Finn, Toll-like receptor 4 or 2 agonists decrease allergic inflammation. Am J Respir Cell Mol Biol., 32: 218-224, 2005.
95. S. Bauer, D. Hangel, and P. Yu, Immunobiology of Toll-like receptors in allergic disease. Immunobiology., 212: 521-533, 2007.
96. A. Fukushima, T. Yamaguchi, W. Ishida, K. Fukata, and H. Ueno, TLR2 agonist ameliorates murine experimental allergic conjunctivitis by inducing CD4 positive T-cell apoptosis rather than by affecting the Th1/Th2 balance. Biochem Biophys Res Commun., 339: 1048-1055, 2006.
97. M.E. Bashir, S. Louie, H.N. Shi, and C. Nagler-Anderson, Toll-like receptor 4 signaling by intestinal microbes influences susceptibility to food allergy. J Immunol., 172: 6978-6987, 2004.
98. E. Stockfleth, U. Trefzer, C. Garcia-Bartels, T. Wegner, T. Schmook, and W. Sterry. The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview. Br J Dermatol., 149 (Suppl 66): 53-56, 2003.
99. Boraska Jelavi T, M. Barisi, Drmic Hofman I, V. Boraska, E. Vrdoljak, M. Peruzovi, I. Hozo, Z. Puljiz, and J. Terzie, Microsatelite GT polymorphism in the Toll-like receptor 2 is associated with colorectal cancer. Clin Genet., 70: 156-160, 2006.
100. M. Fukata, A. Chen, A.S. Vamadevan, J. Cohen, K. Breglio, S. Krishnareddy, D. Hsu, R. Xu, N. Harpaz, A.J. Dannenberg, K. Subbaramaiah, H.S. Cooper, S.H. Itzkowitz, and M.T. Abreu, Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology., 133: 1869-1881, 2007.
101. S.L. Zheng, K. Augustsson-Bälter, B. Chang, M. Hedelin, L. Li, H.O. Adami, J. Bensen, G. Li, J.E. Johnasson, A.R. Turner, T.S. Adams, D.A. Meyers, W.B. Isaacs, J. Xu, and H. Grönberg, Sequence variants of Toll-like receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden Study. Cancer Res., 64: 2918-2922, 2004.
102. J. Sun, F. Wiklund, S.L. Zheng, B. Chang, K. Bälter, L. Li, J.E. Johansson, G. Li, H.O. Adami, W. Liu, A. Tolin, A.R. Turner, D.A. Meyers, W.B. Isaacs, and J. Xu, H. Grönberg, Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J Natl Cancer Inst., 97: 525-532, 2005.
103. Y.C. Chen, E. Giovannucci, R. Lazarus, P. Kraft, S. Ketkar, and D.J. Hunter, Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res., 65: 11771-11778, 2005.
104. I. Cheng, S.J. Plummer, G. Casey, and J.S. Witte, Toll-like receptor 4 genetic variation and advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev., 16: 352-355, 2007.
105. T. Tahara, T. Arisawa, F. Wang, T. Shibata, M. Nakamura, M. Sakata, I. Hirata, and H. Nakano, Toll-like receptor 2 -196 to 174del polymorphism influences the susceptibility of Japanese people to gastric cancer. Cancer Sci., 98: 1790-1794, 2007.
106. G.L. Hold, C.S. Rabkin, W.H. Chow, M.G. Smith, M.D. Gammon, H.A. Risch, T.L. Vaughan, K.E. McColl, J. Lissowska, W. Zatonski, J.B. Schoenberg, W.J. Blot, N.A. Mowat, J.F. Fraumeni Jr., and E.M. El-Omar, A functional polymorphism of Toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology., 132: 905-912, 2007.
107. D.E. Spaner, Y. Shi, D. White, J. Mena, C. Hammond, J. Tomic, L. He, M.A. Tomai, R.L. Miller, J. Booth, and L. Radvanyi, Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells. Leukemia., 20: 286-295, 2006.
108. M.R. Chicoine, M. Zahner, E.K. Won, R.R. Kalra, T. Kitamura, A. Perry, and R. Higashikubo, The in vivo antitumoral effects of lipopolysaccharide against glioblastoma multiforme are mediated in part by Toll-like receptor 4. Neurosurgery., 60: 372-380, 2007.
109. A. Nieters, L. Beckmann, E. Deeg, and N. Becker, Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk. Genes Immun., 7: 615-624. 2006.
110. J. Li, W. Song, D.K. Czerwinski, B. Varghese, S. Uematsu, S. Akira, A.M. Krieg, and R. Levy, Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol., 179: 2493-2500, 2007.
111. W.Y. Kim, J.W. Lee, J.J. Choi, C.H. Choi, T.J. Kim, B.G. Kim, S.Y. Song, and D.S. Bae, Increased expression of Toll-like receptor 5 during progression of cervical neoplasia. Int J Gynecol Cancer., 18(2): 300-305, 2008.
112. J.W. Lee, J.J. Choi, E.S. Seo, M.J. Kim, W.Y. Kim, C.H. Choi, T.J. Kim, B.G. Kim, S.Y. Song, and D.S. Bae, Increased Toll-like receptor 9 expression in cervical neoplasia. Mol Carcinog., 46: 941-917, 2007.
113. M. Pashenkov, G. Goëss, C. Wagner, M. Hörmann, T. Jandl, A. Moser, C.M. Britten, J. Smolle, S. Koller, C. Mauch, I. Tantcheva-Poor, S. Grabbe, C. Loquai, S. Esser, T. Franckson, A. Schneeberger, C. Haarmann, A.M. Krieg, G. Stingl, and S.N. Wagner, Phase II trial of a Toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol., 24: 5716-5724, 2006.
114. S. Kiechl, C.J. Wiedermann, and J. Willeit, Toll-like receptor 4 and atherogenesis. Ann Med., 35: 164-171, 2003.
115. M. Shinohara, K. Hirata, T. Yamashita, T. Takaya, N. Sasaki, R. Shiraki, T. Ueyama, N. Emoto, N. Inoue, M. Yokoyama, and S. Kawashima, Local overexpression of Toll-like receptors at the vessel wall induces atherosclerotic lesion formation: synergism of TLR2 and TLR4. Arterioscler Thromb Vasc Biol., 27: 2384-2391, 2007.
116. G. Pasterkamp, J.K. Van Keulen, and D.P. De Kleijn, Role of Toll-like receptor 4 in the initiation and progression of atherosclerotic disease. Eur J Clin Invest., 34: 328-334, 2004.
117. R. Arroyo-Espliguero, P. Avanzas, S. Jeffery, and J.C. Kaski, CD14 and Toll-like receptor 4: a link between infection and acute coronary events? Heart., 90: 983-988, 2004.
118. L.L. Stoll, G.M. Denning, and N.L. Weintraub, Endotoxin, TLR4 signaling and vascular inflammation: potential therapeutic targets in cardiovascular disease. Curr Pharm Des., 12: 4229-4245, 2006.
119. A.E. Mullick, P.S. Tobias, and L.K. Curtiss, Modulation of atherosclerosis in mice by Toll-like receptor 2. J Clin Invest., 115: 3149-3156, 2005.
120. A.H. Schoneveld, M.M. Oude Nijhuis, B. vanMiddelaar, J.D. Laman, D.P. de Kleijn, and G. Pasterkamp, Toll-like receptor 2 stimulation induces intimal hyperplasia and atherosclerotic lesion development. Cardiovasc Res., 66: 162-169, 2005.
121. J. Favre, P. Musette, V. Douin-Echinard, K. Laude, J.P. Henry, J.F. Arnal, and C. Thuillez, Richard VToll-like receptors 2-deficient mice are protected against postischemic coronary endothelial dysfunction. Arterioscler Thromb Vasc Biol., 27: 1064-1071, 2007.
122. N. Ameziane, T. Beillat, P. Verpillat, S. Chollet-Martin, M.C. Aumont, P. Seknadji, M. Lamotte, D. Lebret, V. Ollivier, and D. de Prost, Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler Thromb Vasc Biol. 2003 23: e61-64.
123. H.L. Geng, H.Q. Lu, L.Z. Zhang, H. Zhang, L. Zhou, H. Wang, and R.Q. Zhong, Increased expression of Toll like receptor 4 on peripheral-blood mononuclear cells in patients with coronary arteriosclerosis disease. Clin Exp Immunol., 143: 269-273, 2006.
124. J.W. Holloway, I.A. Yang, and S Ye, Variation in the Toll-like receptor 4 gene and susceptibility to myocardial infarction. Pharmacogenet Genomics., 15: 15-21, 2005.
125. K. Karikó, D. Weissman, and F.A. Welsh, Inhibition of Toll-like receptor and cytokine signaling-a unifying theme in ischemic tolerance. Cereb Blood Flow Metab. 24: 1288-1304, 2004.
126. J.E. McInturff, R.L. Modlin, and J. Kim, The role of Toll-like receptors in the pathogenesis and treatment of dermatological disease. J Invest Dermatol., 125: 1-8, 2005.
127. B.S. Baker, J.M. Ovigne, A.V. Powles, S. Corcoran, and L. Fry, Normal keratinocytes express Toll-like receptors (TLRs) 1, 2 and 5: modulation of TLR expression in chronic plaque psoriasis. Br J Dermatol., 148: 670-679, 2003.
128. J. Kim, M.T. Ochoa, S.R. Krutzik, O. Takeuchi, S. Uematsu, A.J. Legaspi, H.D. Brightbill, D. Holland, W.J. Cunliffe, S. Akira, P.A. Sieling, P.J. Godowski, and R.L. Modlin, Activation of Toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol., 169: 1535-1541, 2002.
129. M. Ueta, C. Sotozono, T. Inatomi, K. Kojima, K. Tashiro, J. Hamuro, and S. Kinoshita, Toll-like receptor 3 gene polymorphisms in Japanese patients with Stevens-Johnson syndrome. Br J Ophthalmol., 91: 962-965, 2007.
130. E. Cario, and D.K. Podolsky, Differential alteration in intestinal epithelial cell expression of Toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun., 68: 7010-7017, 2000.
131. E. Cario, Toll-like receptors and intestinal defence: molecular basis and therapeutic implications. Expert Rev Mol Med., 5: 1-15, 2003.
132. D. Franchimont, S. Vermeire, H. El Housni, M. Pierik, K. Van Steen, T. Gustot, E. Quertinmont, M. Abramowicz, A. Van Gossum, J. Devìere, and P. Rutgeerts, Deficient host-bacteria interactions in inflammatory bowel disease? The Toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut., 53: 987-992, 2004.
133. J. Hong, E. Leung, A.G. Fraser, T.R. Merriman, P. Vishnu, and G.W. Krissansen: TLR2, TLR4 and TLR9 polymorphisms and Crohn's disease in a New Zealand Caucasian cohort. J Gastroenterol Hepatol., 22: 1760-1766, 2007.
134. S. Brand, T. Staudinger, F. Schnitzler, S. Pfennig, K. Hofbauer, J. Dambacher, J. Seiderer, C. Tillack, A. Konrad, A. Crispin, B. Göke, P. Lohse, and T. Ochsenkühn, The role of Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease. Inflamm Bowel Dis., 11: 645-652, 2005.
135. M.G. Netea, B.J. Kullberg, D.J. de Jong, B. Franke, T. Sprong, T.H. Naber, J.P. Drenth, and J.W. Van der Meer, NOD2 mediates anti-inflammatory signals induced by TLR2 ligands: implications for Crohn's disease. Eur J Immunol., 34: 2052-2059, 2004.
136. K. Katakura, J. Lee, D. Rachmilewitz, G. Li, L. Eckmann, and E. Raz, Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J Clin Invest., 115: 695-702, 2005.
137. M. Vijay-Kumar, C.J. Sanders, R.T. Taylor, A. Kumar, J.D. Aitken, S.V. Sitaraman, A.S. Neish, S. Uematsu, S. Akira, I.R. Williams, and A.T. Gewirtz: Deletion of TLR5 results in spontaneous colitis in mice. J Clin Invest., 117: 3909-3921, 2007.
138. M.T. Abreu, Immunologic regulation of Toll-like receptors in gut epithelium. Curr Opin Gastroenterol., 19: 559-564, 2003.
139. L.E. Oostenbrug, J.P. Drenth, D.J. de Jong, I.M. Nolte, E. Oosterom, H.M. van Dullemen, K. van der Linde, G.J. te Meerman, G. van der Steege, J. H. Kleibeuker, and P.L. Jansen, Association between Toll-like receptor 4 and inflammatory bowel disease. Inflamm Bowel Dis., 11: 567-575, 2005.
140. M. Pierik, S. Joossens, K. Van Steen, N. Van Schuerbeek, R. Vlietinck, P. Rutgeerts, and S. Vermeire, Toll-like receptor-1, -2, and -6 polymorphisms influence disease extension in inflammatory bowel diseases. Inflamm Bowel Dis., 12: 1-8, 2006.
141. L. Frolova, P. Drastich, P. Rossmann, K. Klimesova, and H. Tlaskalova-Hogenova: Expression of Toll-like receptor 2 (TLR2), TLR4, and CD14 in biopsy samples of patients with inflammatory bowel diseases: upregulated expression of TLR2 in terminal ileum of patients with ulcerative colitis. J Histochem Cytochem., 56(3): 267-274, 2008.
142. B. Szebeni, G. Veres, A. Dezsõfi, K. Rusai, A. Vannay, M. Mraz, E. Majorova, and A. Arató, Increased expression of Toll-like receptor (TLR) 2 and TLR4 in the colonic mucosa of children with inflammatory bowel disease. Clin Exp Immunol., 151: 34-41, 2008.
143. B. Szebeni, G. Veres, A. Dezsofi, K. Rusai, A. Vannay, G. Bokodi, B. Vásárhelyi, I.R. Korponay-Szabó, T. Tulassay, and A. Arató, Increased mucosal expression of Toll-like receptor (TLR)2 and TLR4 in coeliac disease. J Pediatr Gastroenterol Nutr., 45: 187-193, 2007.
144. D.J. van Westerloo, S. Weijer, M.J. Bruno, A.F. de Vos, C. Van't Veer, and T. van der Poll, Toll-like receptor 4 deficiency and acute pancreatitis act similarly in reducing host defense during murine Escherichia coli peritonitis. Crit Care Med., 33: 1036-1043, 2005.
145. C.L. Leaphart, J. Cavallo, S.C. Gribar, S. Cetin, J. Li, M.F. Branca, T.D. Dubowski, C.P. Sodhi, and D.J. Hackam, A critical role for TLR4 in the pathogenesis of necrotizing enterocolitis by modulating intestinal injury and repair. J Immunol., 179: 4808-4820, 2007.
146. Y. Takii, M. Nakamura, M. Ito, T. Yokoyama, A. Komori, Y. Shimizu-Yoshida, R. Nakao, K. Kusumoto, S. Nagaoka, K. Yano, S. Abiru, T. Ueki, T. Matsumoto, M. Daikoku, K. Taniguchi, H. Fujioka, K. Migita, H. Yatsuhashi, M. Nakashima, M. Harada, and H. Ishibashi, Enhanced expression of type I interferon and Toll-like receptor-3 in primary biliary cirrhosis. Lab Invest., 85: 908-820, 2005.
147. A.P. Wang, K. Migita, M. Ito, Y. Takii, M. Daikoku, T. Yokoyama, A. Komori, M. Nakamura, H. Yatsuhashi, and H. Ishibashi, Hepatic expression of Toll-like receptor 4 in primary biliary cirrhosis. J Autoimmun., 25: 85-91, 2005.
148. G. Zuo, J. Gong, C. Liu, C. Wu, S. Li, and L. Dai, Synthesis of Toll-like receptor 4 in Kupffer cells and its role in alcohol-induced liver disease. Chin Med J (Engl)., 116: 297-300, 2003.
149. L. Wang, J.B. Xu, H.S. Wu, J.X. Zhang, J.H. Zhang, Y. Tian, and C.Y. Wang, The relationship between activation of TLR4 and partial hepatic ischemia/reperfusion injury in mice. Hepatobiliary Pancreat Dis Int., 5: 101-104, 2006.
150. J.M. Prince, R.M. Levy, R. Yang, K.P. Mollen, M.P. Fink, Y. Vodovotz, and T.R. Billiar, Toll-like receptor-4 signaling mediates hepatic injury and systemic inflammation in hemorrhagic shock. J Am Coll Surg., 202: 407-417, 2006.
151. S.F. Saturnino, and M.V. Andrade, Toll-like receptors, new horizons in sepsis. Curr Mol Med., 7: 522-531, 2007.
152. Zuany-C. Amorim, J. Hastewell, and C. Walker, Toll-like receptors as potential therapeutic targets for multiple diseases. Nat Rev Drug Discov., 1: 797-807, 2002.
153. J.H. Chang, P.J. McCluskey, and D. Wakefield, Toll-like receptors in ocular immunity and the immunopathogenesis of inflammatory eye disease. Br J Ophthalmol., 90: 103-108, 2006.
154. A. Berdeli, H.A. Celik, R. Ozyürek, B. Dogrusoz, and H.H. Aydin, TLR-2 gene Arg753Gln polymorphism is strongly associated with acute rheumatic fever in children. J Mol Med., 83: 535-541, 2005.
155. T. Fukusaki, N. Ohara, Y. Hara, A. Yoshimura, and K. Yoshiura, Evidence for association between a Toll-like receptor 4 gene polymorphism andmoderate/severe periodontitis in the Japanese population. J Periodontal Res., 42: 541-545, 2007.
156. M. Emonts, R.H. Veenhoven, S.P. Wiertsema, J.J. Houwing-Duistermaat, V. Walraven, R. de Groot, P.W. Hermans, and E.A. Sanders, Genetic polymorphisms in immunoresponse genes TNFA, IL6, IL10, and TLR4 are associated with recurrent acute otitis media. Pediatrics., 120: 814-823, 2007.
157. S. Pabst, G. Baumgarten, A. Stremmel, M. Lennarz, P. Knüfermann, A. Gillissen, H. Vetter, and C. Grohé, Toll-like receptor (TLR) 4 polymorphisms are associated with a chronic course of sarcoidosis. Clin Exp Immunol., 143: 420-426, 2006.
158. T. Kielian, Toll-like receptors in central nervous system glial inflammation and homeostasis. J Neurosci Res., 83: 711-730, 2006.
159. A.C. Jackson, J.P. Rossiter, and M. Lafon, Expression of Toll-like receptor 3 in the human cerebellar cortex in rabies, herpes simplex encephalitis, and other neurological diseases. J Neurovirol., 12: 229-234, 2006.
160. K. Chen, P. Iribarren, J. Hu, J. Chen, W. Gong, E.H. Cho, S. Lockett, N.M. Dunlop, and J.M. Wang, Activation of Toll-like receptor 2 on microglia promotes cell uptake of Alzheimer disease-associated amyloid beta peptide. J Biol Chem., 281: 3651-3659, 2006.
161. B.N. Nessa, T. Tanaka, K. Kamino, G. Sadik, A.B. Ansar, R. Kimura, H. Tanii, M. Okochi, T. Morihara, S. Tagami, T. Kudo, and M. Takeda, Toll-like receptor 3 mediated hyperphosphorylation of tau in human SH-SY5Y neuroblastoma cells. Psychiatry Clin Neurosci., 60 (Suppl 1): S27-33, 2006.
162. S. Walter, M. Letiembre, Y. Liu, H. Heine, B. Penke, W. Hao, B. Bode, N. Manietta, J. Walter, W. Schulz-Schuffer, and K. Fassbender, Role of the Toll-like receptor 4 in neuroinflammation in Alzheimer's disease. Cell Physiol Biochem., 20: 947-56, 2007.
163. M. Prinz, F. Garbe, H. Schmidt, A. Mildner, I. Gutcher, K. Wolter, M. Piesche, R. Schroers, E. Weiss, C.J. Kirschning, C.D. Rochford, W. Brück, and B. Becher, Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J Clin Invest., 116: 456-456, 2006.
164. L.H. Guo and H.J. Schluesener, The innate immunity of the central nervous system in chronic pain: the role of Toll-like receptors. Cell Mol Life Sci., 64: 1128-1136, 2007.
165. T.G. Krediet, S.P. Wiertsema, M.J. Vossers, S.B. Hoeks, A. Fleer, H.J. Ruven, and G.T. Rijkers, Toll-like receptor 2 polymorphism is associated with preterm birth. Pediatr Res., 62(4): 474-476, 2007.
166. N. Chaudhuri, S.K. Dower, M.K. Whyte, and I. Sabroe, Toll-like receptors and chronic lung disease. Clin Sci (Lond)., 109: 125-33, 2005.
167. W. Eder, W. Klimecki, L. Yu, E. von Mutius, J. Riedler, C. Braun-Fahrländer, D. Nowak, and F.D. Martinez, ALEX Study Team. Toll-like receptor 2 as a major gene for asthma in children of European farmers. J Allergy Clin Immunol., 113: 482-488, 2004.
168. K. Tantisira, W.T. Klimecki, R. Lazarus, L.J. Palmer, B.A. Raby, D.J. Kwiatkowski, E. Silverman, D. Vercelli, F.D. Martinez, and S.T. Weiss, Toll-like receptor 6 gene (TLR6): single-nucleotide polymorphism frequencies and preliminary association with the diagnosis of asthma. Genes Immun., 5: 343-346, 2004.
169. S. Phipps, C.E. Lam, P.S. Foster, and K.I. Matthaei, The contribution of Toll-like receptors to the pathogenesis of asthma. Immunol Cell Biol., 85: 463-470, 2007.
170. H. Revets, G. Pynaert, J. Grooten, P. De Baetselier, and I. Lipoprotein, a TLR2/4 ligand modulates Th2-driven allergic immune responses.J Immunol., 174: 1097-1103, 2005.
171. S. Hoffjan, S. Stemmler, Q. Parwez, E. Petrasch-Parwez, U. Arinir, G. Rohde, K. Reinitz-Rademacher, G. Schultze-Werninghaus, A. Bufe, and J.T. Epplen, Evaluation of the Toll-like receptor 6 Ser249Pro polymorphism in patients with asthma, atopic dermatitis and chronic obstructive pulmonary disease. BMC Med Genet., 6: 34, 2005.
172. R. Lazarus, B.A. Raby, C. Lange, E.K. Silverman, D.J. Kwiatkowski, D. Vercelli, W.J. Klimecki, F.D. Martinez, and S.T. Weiss, Toll-like receptor 10 genetic variation is associated with asthma in two independent samples. Am J Respir Crit Care Med., 170: 594-600, 2004
173. D. Droemann, T. Goldmann, T. Tiedje, P. Zabel, K. Dalhoff, and B. Schaaf, Toll-like receptor 2 expression is decreased on alveolar macrophages in cigarette smokers and COPD patients. Respir Res., 6: 68, 2005.
174. G. Rohde, W. Klein, U. Arinir, M. Hagedorn, N. Duerig, T.T. Bauer, A. Gillissen, G. Schultze-Werninghaus, and T Epplen J, Association of the ASP299GLY TLR4 polymorphism with COPD. Respir Med., 100: 892-896, 2006.
175. H.P. Hauber, M.K. Tulic, A. Tsicopoulos, B. Wallaert, R. Olivenstein, P. Daigneault, and Q. Hamid, Toll-like receptors 4 and 2 expression in the bronchial mucosa of patients with cystic fibrosis. Can Respir J., 12: 13-8, 2005.
176. X. Zhang, P. Shan, G. Jiang, L. Cohn, and P.J. Lee, Toll-like receptor 4 deficiency causes pulmonary emphysema. J Clin Invest. 116: 3050-3059, 2006.
177. H.J. Anders and D. Schlöndorff, Toll-like receptors: emerging concepts in kidney disease. Curr Opin Nephrol Hypertens., 16: 177-183, 2007,
178. Ann Med., 35: 164-71, 2003.
179. P.S. Patole, R.D. Pawar, J. Lichtnekert, M. Lech, O.P. Kulkarni, A. Ramanjaneyulu, S. Segerer, and H.J. Anders, Coactivation of Toll-like receptor-3 and -7 in immune complex glomerulonephritis. J Autoimmun., 29: 52-9, 2007.
180. B. Liu, Y. Yang, J. Dai, R. Medzhitov, M.A. Freudenberg, P.L. Zhang, and Z. Li, TLR4 up-regulation at protein or gene level is pathogenic for lupus-like autoimmune disease. J Immunol., 177: 6880-6888, 2006.
181. K.P. Mollen, R.J. Anand, A. Tsung, J.M. Prince, R.M. Levy, and T.R. Billiar, Emerging paradigm: Toll-like receptor 4-sentinel for the detection of tissue damage. Shock., 26: 430-437, 2006.
182. Z. Zhang and H.J. Schluesener, Mammalian Toll-like receptors: from endogenous ligands to tissue regeneration. Cell Mol Life Sci., 63: 2901-2907, 2006.
183. B. Dybdahl, A. Wahba, E. Lien, T.H. Flo, A. Waage, N. Qureshi, O.F. Sellevold, T. Espevik, and A. Sundan, Inflammatory response after open heart surgery: release of heat-shock protein 70 and signaling through Toll-like receptor-4. Circulation., 105: 685-690, 2002.
184. S.C. Tang, T.V. Arumugam, X. Xu, A. Cheng, M.R. Mughal, D.G. Jo, J.D. Lathia, D.A. Siler, S. Chigurupati, X. Ouyang, T. Magnus, S. Camandola, and M.P. Mattson, Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci U S A., 104: 13798-13803, 2007.
185. S. Lehnardt, S. Lehmann, D. Kaul, K. Tschimmel, O. Hoffmann, S. Cho, C. Krueger, R. Nitsch, A. Meisel, and J.R. Weber, Toll-like receptor 2 mediates CNS injury in focal cerebral ischemia. J Neuroimmunol., 190: 28-33, 2007.
186. T.J. Murphy, H.M. Paterson, S. Kriynovich, Y. Zang, E.A. Kurt-Jones, J.A. Mannick, and J.A. Lederer, Linking the "two-hit" response following injury to enhanced TLR4 reactivity. J Leukoc Biol., 77: 16-23, 2005.
187. R.C. Barber, C.C. Aragaki, F.A. Rivera-Chavez, G.F. Purdue, J.L. Hunt, and J.W. Horton, TLR4 and TNF-alpha polymorphisms are associated with an increased risk for severe sepsis following burn injury. J Med Genet., 41: 808-813, 2004.
188. A. Shimamoto, T.H. Pohlman, S. Shomura, T. Tarukawa, M. Takao, and H. Shimpo, Toll-like receptor 4 mediates lung ischemia-reperfusion injury. Ann Thorac Surg., 82: 2017-2023, 2006.
189. Comment in: Ann Thorac Surg., 82: 2023, 2006.
190. I. Santin, J.R. Bilbao, G.P. de Nanclares, B. Calvo, and Castaño L, No association of TLR2 and TLR4 polymorphisms with type I diabetes mellitus in the Basque population. Ann N Y Acad Sci., 1079: 268-72, 2006.
191. I. Santin, A. Castellanos-Rubio, I. Hualde, L. Castaño, J.C. Vitoria, and J.R. Bilbao, Toll-like receptor 4 (TLR4) gene polymorphisms in celiac disease. Tissue Antigens., 70: 495-8, 2007.
192. K.S. Na, T.H. Kim, P. Rahman, L. Peddle, C.B. Choi, and R.D. Inman, Analysis of single nucleotide polymorphisms in Toll-like receptor 4 shows no association with ankylosing spondylitis in a Korean population. Rheumatol Int., 2007.
193. F.J. Sheedy, I. Marinou, L.A. O'Neill, and A.G. Wilson, The Mal/TIRAP S180L and TLR4 G299D polymorphismsare not associated with susceptibility to or severity of rheumatoid arthritis. Ann Rheum Dis., 2008.
194. F.Y. Demirci, S. Manzi, R. Ramsey-Goldman, M. Kenney, P.S. Shaw, -C. Dunlop M. Thomas, A.H. Kao, E.Y. Rhew, F. Bontempo, C. Kammerer, and M.I. Kamboh, Association study of Toll-like receptor 5 (TLR5) and Toll-like receptor 9 (TLR9) polymorphisms in systemic lupus erythematosus. J Rheumatol., 34: 1708-1711, 2007.
195. Comment in: J Rheumatol., 34: 1641-1642, 2007.
196. M.G. Netea, C. van der Graaf, J.W. M. van der Meer, and B.J. Kullberg, Toll-like receptors and the host defense against microbial pathogens: bringing specificity to the innate-immune system. J Leukoc Biol., 75: 749-755, 2004.
197. K. Oda and H. Kitano, A comprehensive map of the Toll-like receptor signaling network. Mol Syst Biol., 2: 1-20, 2006.